Tumor microenvironment targets and potential therapies
| Category . | Target . | Potential agents . |
|---|---|---|
| Immunomodulatory agents | Multiple | Lenalidomide |
| Immune checkpoint inhibitors | PD-1 | Pidilizumab |
| PD-1 | Nivolumab | |
| PD-1 | Pembrolizumab | |
| PD-1 | MEDI-0680 | |
| PD-L1 | Durvalumab | |
| PD-L1 | Atezolizumab | |
| CTLA-4 | Ipilimumab | |
| Other immunomodulatory agents | CD47 | TTI-621 |
| CD137 | Urelumab | |
| KIR | Lirilumab |
| Category . | Target . | Potential agents . |
|---|---|---|
| Immunomodulatory agents | Multiple | Lenalidomide |
| Immune checkpoint inhibitors | PD-1 | Pidilizumab |
| PD-1 | Nivolumab | |
| PD-1 | Pembrolizumab | |
| PD-1 | MEDI-0680 | |
| PD-L1 | Durvalumab | |
| PD-L1 | Atezolizumab | |
| CTLA-4 | Ipilimumab | |
| Other immunomodulatory agents | CD47 | TTI-621 |
| CD137 | Urelumab | |
| KIR | Lirilumab |